Template:Second-generation BTKi table: Difference between revisions
From Embryology
mNo edit summary |
mNo edit summary |
||
Line 1: | Line 1: | ||
{| | {| | ||
|+ ''' | |+ '''Second-generation Bruton’s Tyrosine Kinase Inhibitors (BTKi) for CCL Treatment''' | ||
|-bgcolor="CEDFF2" | |-bgcolor="CEDFF2" | ||
! width=110px|BTK inhibitor | ! width=110px|BTK inhibitor |
Latest revision as of 14:11, 30 April 2019
BTK inhibitor | BTK binding mechanism | Selectivity for BTK | Relevant non-BTK targets | Clinical Phase |
---|---|---|---|---|
Acalabrutinib | Covalent, irreversible | High | N/A | II/III |
Zanubrutinib | Covalent, irreversible | Moderate | N/A | II/III |
Tirabrutinib | Covalent, irreversible | High | N/A | I/II |
Vecabrutinib | Non-covalent, reversible | Moderate | interleukin-2-inducible (ITK) | I/II |
LOXO-305 | Non-covalent, reversible | High | N/A | I |
ARQ-531 | Non-covalent, reversible | Low | Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) |
I |
Table data [1] |